Cargando…

Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study

Hypernatremia (>145 mmol/L) is a relatively rare event, and the data regarding its role in the outcome of inpatients on an oncology ward are weak. The aim of this study was to describe the prevalence, prognosis, and outcome of hospitalized cancer patients with hypernatremia. We performed a retros...

Descripción completa

Detalles Bibliográficos
Autores principales: del Rio, Jessica, Buess, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689174/
https://www.ncbi.nlm.nih.gov/pubmed/36421346
http://dx.doi.org/10.3390/curroncol29110693
_version_ 1784836463597191168
author del Rio, Jessica
Buess, Martin
author_facet del Rio, Jessica
Buess, Martin
author_sort del Rio, Jessica
collection PubMed
description Hypernatremia (>145 mmol/L) is a relatively rare event, and the data regarding its role in the outcome of inpatients on an oncology ward are weak. The aim of this study was to describe the prevalence, prognosis, and outcome of hospitalized cancer patients with hypernatremia. We performed a retrospective case-control study of data obtained from inpatients with a solid tumor at the St. Claraspital, Basel, Switzerland, who were admitted between 2017 and 2020. The primary endpoint was overall survival. Hypernatremia was found in 93 (3.16%) of 2945 inpatients bearing cancer or lymphoma. From 991 eligible normonatremic control patients, 93 were matched according to diagnosis, age, and sex. The median overall survival time (OS) of patients with hypernatremia was 1.5 months compared to 11.7 months of the normonatremic controls (HR 2.69, 95% CI 1.85–3.90, p < 0.0001). OS of patients with irreversible compared to reversible hypernatremia was significantly shorter (23 versus 88 days, HR 4.0, 95% CI 2.04–7.70, p < 0.0001). The length of hospital stay was significantly longer for the hypernatremic than for the normonatremic group (p < 0.0001). Significantly more patients with hypernatremia died in the hospital (30.1% versus 8.6%, p < 0.001). These results suggest hypernatremia to be associated with an unfavorable outcome and a very short OS.
format Online
Article
Text
id pubmed-9689174
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96891742022-11-25 Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study del Rio, Jessica Buess, Martin Curr Oncol Article Hypernatremia (>145 mmol/L) is a relatively rare event, and the data regarding its role in the outcome of inpatients on an oncology ward are weak. The aim of this study was to describe the prevalence, prognosis, and outcome of hospitalized cancer patients with hypernatremia. We performed a retrospective case-control study of data obtained from inpatients with a solid tumor at the St. Claraspital, Basel, Switzerland, who were admitted between 2017 and 2020. The primary endpoint was overall survival. Hypernatremia was found in 93 (3.16%) of 2945 inpatients bearing cancer or lymphoma. From 991 eligible normonatremic control patients, 93 were matched according to diagnosis, age, and sex. The median overall survival time (OS) of patients with hypernatremia was 1.5 months compared to 11.7 months of the normonatremic controls (HR 2.69, 95% CI 1.85–3.90, p < 0.0001). OS of patients with irreversible compared to reversible hypernatremia was significantly shorter (23 versus 88 days, HR 4.0, 95% CI 2.04–7.70, p < 0.0001). The length of hospital stay was significantly longer for the hypernatremic than for the normonatremic group (p < 0.0001). Significantly more patients with hypernatremia died in the hospital (30.1% versus 8.6%, p < 0.001). These results suggest hypernatremia to be associated with an unfavorable outcome and a very short OS. MDPI 2022-11-16 /pmc/articles/PMC9689174/ /pubmed/36421346 http://dx.doi.org/10.3390/curroncol29110693 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
del Rio, Jessica
Buess, Martin
Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study
title Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study
title_full Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study
title_fullStr Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study
title_full_unstemmed Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study
title_short Outcome of Hospitalized Cancer Patients with Hypernatremia: A Retrospective Case-Control Study
title_sort outcome of hospitalized cancer patients with hypernatremia: a retrospective case-control study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689174/
https://www.ncbi.nlm.nih.gov/pubmed/36421346
http://dx.doi.org/10.3390/curroncol29110693
work_keys_str_mv AT delriojessica outcomeofhospitalizedcancerpatientswithhypernatremiaaretrospectivecasecontrolstudy
AT buessmartin outcomeofhospitalizedcancerpatientswithhypernatremiaaretrospectivecasecontrolstudy